The Quiet Revolution: Why Agricultural Genetic Engineering Is Entering Its Biggest Boom Yet

Biology is becoming the new software—and the farm, the field, and the ocean are becoming its most consequential deployment environments.

At Speciale, we're always watching for technologies that fundamentally reshape human progress, from space travel to fusion energy. One of the most compelling spaces we're tracking right now is happening in agriculture. After decades of incremental progress and regulatory battles, agricultural genetic engineering is finally reaching commercial scale. This transformation will reshape the world much like we did when we learned to synthesize urea—splitting a nitrogen triple bond was no small feat, and if you have time, I'd highly recommend watching the story of how that happened.

The numbers tell a striking story. Funding for agri-gene-editing startups surged 206% in H1 2024, reaching $161 million. Inari secured $144 million in January 2025, bringing their total equity raised to over $720 million. Pivot Bio has raised nearly $700 million and now operates on 15 million acres. Pairwise hit $155 million and launched North America's first CRISPR-edited food product. These aren't seed-stage experiments anymore—they're scaled platforms with real commercial traction.

Why Now: When Necessity Meets Capability

Traditional breeding alone cannot meet future productivity requirements. Population pressures, climate volatility, water scarcity, and collapsing soil fertility have created a biological ceiling that technology must breach. Many regions already face stagnant yields in rice, wheat, and maize—the staples that feed billions.

But necessity alone doesn't explain the timing. What's changed is capability.

Before 2012, genetic modification required expensive, slow transgenic processes. Today, CRISPR-Cas systems, base editors, and prime editors allow precise single-base edits, trait stacking, and multiplex editing of complex polygenic traits. Critically, non-transgenic edits now bypass regulatory drag in several jurisdictions. The cost of creating a modified crop variety has fallen by an order of magnitude, and timelines have compressed from seven to ten years down to eighteen to thirty-six months.

This is the agricultural equivalent of what AlphaFold did for drug discovery—taking processes that were artisanal and making them computational.

The Technical Stack: From Guesswork to Predictive Design

Next-generation ag-biotech companies like Inari, Benson Hill, and Evogene are building computational platforms that model plant genomes, simulate trait interactions, predict regulatory element behavior, and optimize metabolic pathways. This transforms crop engineering from trial-and-error into predictive design.

Inari's SEEDesign platform exemplifies this approach. Using AI and multiplex gene editing, they're developing soybeans, corn, and wheat with dramatically improved yields and resource efficiency, targeting ten to twenty percent yield increases while reducing water and nitrogen use by forty percent in corn. Their technology is distinct from traditional GMO approaches—it can be licensed directly to seed companies and faces lighter regulatory pathways.

Pairwise's Fulcrum Platform integrates CRISPR, AI, and plant biology to accelerate climate-ready, disease-tolerant crops. Their proprietary SHARC enzyme enables not just gene knockouts but precise tuning—finding the sweet spot for trait expression rather than simply switching genes on or off.

The Microbiome Play: From Chemistry to Biology

Perhaps the most underappreciated shift is the rise of engineered microbes as agricultural inputs. Nitrogen fertilizer alone contributes roughly five percent of worldwide climate emissions, pollutes groundwater, and degrades soil. It's a $200+ billion market ripe for disruption.

Pivot Bio has cracked this problem. Their genetically edited microbes colonize plant roots, consume sugars, and produce nitrogen directly where plants need it—replacing up to forty pounds per acre of synthetic fertilizer. The validation data is impressive: the technology has been applied on nearly fifteen million cumulative acres, up from five million in 2024 and one million in 2022. Across 172 fields, 97 counties, and 20 states, they've demonstrated 37 pounds per acre nitrogen reduction with yield parity maintained and 16% improved nitrogen-use efficiency.

In December 2024, they launched CERT-N for cotton—the first gene-edited nitrogen product for that crop—replacing twenty percent of synthetic nitrogen while achieving fifty pounds per acre lint yield improvement and 200% first-year ROI. Large-scale trials have been completed across eight states.

The Biopesticide Moment

The biopesticide market has quietly grown to $6.7-8.5 billion in 2024, now representing roughly ten percent of the global pesticide market and growing at 11-15% CAGR. By 2030, projections suggest this market could hit $11-15 billion. What's driving this? Chemical pesticide resistance, regulatory restrictions, consumer demand for organic produce, and critically, the emergence of platform technologies that make discovery scalable.

The most significant regulatory milestone in agricultural biotechnology came in December 2023 when the EPA registered Ledprona—the world's first sprayable dsRNA biopesticide—marketed as Calantha. This is GreenLight Biosciences' RNA pesticide breakthrough. The active ingredient is a 490 base-pair double-stranded RNA targeting the PSMB5 gene in Colorado potato beetle. The dsRNA gets cleaved by DICER into siRNA, which then activates RISC to destroy the target mRNA, blocking protein production and achieving ninety percent larval mortality within six days. The beauty lies in its species-specific precision with minimal non-target effects.

The RNAi pesticides market is projected to grow from $45 million in 2024 to $228 million by 2034 at 17.6% CAGR. Global players including Bayer, Syngenta, Corteva, and BASF are all investing, alongside startups like RNAissance Ag and Forest Innovations.

Meanwhile, Ginkgo Bioworks' acquisition of AgBiome's platform assets in April 2024 consolidated one of the deepest ag biological discovery platforms—115,000+ fully sequenced microbial strains and over 500 million unique gene sequences. And Micropep's antifungal peptide received EPA designation as "biochemical-like," opening regulatory pathways for an entirely new class of crop protection products.

Biofungicides now account for 47.5% of biopesticide sales. Brazil's unified bioinputs law in December 2024 has shortened approval timelines significantly, making it the world's largest biologicals market and the first destination for startups seeking rapid commercialization.

The investment thesis here is clear: biopesticides represent the clearest path for biology to displace legacy chemistry at scale. The winners will be platforms—not products.

Beyond Terrestrial: Oral Biologics for Aquaculture

One of the most underappreciated applications of agricultural biotech is in aquaculture—a $300+ billion global industry where disease management represents an $8.5 billion annual economic burden for shrimp alone. India, the world's largest shrimp exporter, faces acute exposure to this risk.

The core problem is simple but profound: you cannot vaccinate individual shrimp. With millions of larvae per pond, injection-based therapeutics are operationally impossible. Viral diseases like White Spot Syndrome Virus can wipe out an entire operation in under a week, causing 25-30% of shrimp farms to fail annually. WSSV alone causes $3 billion in annual losses and a fifteen percent reduction in global shrimp production. Traditional solutions using antibiotics face regulatory pressure and resistance concerns.

ViAqua Therapeutics from Israel has developed an RNA-particle platform that silences disease-affected genes through feed. Their encapsulated RNA survives the aquatic environment and the shrimp's digestive system, activating cellular responses that disable viral infections. They've raised over $12.5 million, began India production facility operations in early 2024, and have commercial partnerships with Skretting for market distribution. Target markets include Thailand and Ecuador, with their platform adaptable to different diseases by simply changing the RNAi sequence while keeping the same production process.

Peptobiotics in Singapore raised $6.2 million for their antimicrobial peptide platform as antibiotic replacements, addressing the fundamental challenge of manufacturing cost that has blocked peptide commercialization. 

For investors, aquaculture biotech offers a rare combination: urgent market need, clear technical differentiation, and regulatory tailwinds as antibiotic restrictions tighten globally.

The CRISPR Research Frontier

Beyond commercial applications, academic research continues to expand what's possible. The most significant breakthrough came in Nature from researchers at Huazhong Agricultural University and UC Davis. CRISPR editing of the RBL1 gene—a CDP-DAG synthase involved in phospholipid biosynthesis—conferred broad-spectrum resistance to multiple pathogens in rice. A 29-base-pair deletion reduces phosphatidylinositol and PtdIns(4,5)P2, which are disease-susceptibility factors, conferring resistance to rice blast (the world's most serious plant disease), bacterial blight, and other pathogens. Field trials showed fivefold yield improvement versus control in disease-heavy plots.

This represents a paradigm shift: rather than engineering resistance gene by gene for each pathogen, RBL1 editing provides a single intervention with broad-spectrum protection.

Multiple 2024 publications advanced drought tolerance across crops as well. Jennifer Doudna's Innovative Genomics Institute at UC Berkeley is developing drought-tolerant rice with fewer stomata to preserve water, part of what she calls a "coming revolution" in climate-adapted crops.

Technology for delivering CRISPR components is also advancing rapidly—ribonucleoprotein complexes for reduced off-target effects, high-fidelity Cas9 variants, viral vectors, CRISPR-guided transposons for inserting large genetic payloads, and nano-enabled formulations for improved stability and uptake. Beyond traditional CRISPR cuts, base editing and prime editing are being applied across Arabidopsis, cotton, rice, tomato, maize, tobacco, and soybean, with wheat DNA inversions achieving up to 205.4 kb inversions with 51.5% efficiency.

Regulatory Tailwinds

For two decades, political resistance slowed GMO adoption. But the regulatory landscape is undergoing dramatic transformation.

The European Union reached a historic breakthrough after years of deadlock following the 2018 Court of Justice ruling that classified gene-edited crops as GMOs. The December 2025 provisional agreement establishes a modernized framework for New Genomic Techniques with a two-category system. Category 1 NGT plants equivalent to conventionally bred or naturally mutated plants are exempted from GMO legislation with seeds labeled but not consumer products. Category 2 plants remain subject to existing GMO authorization requirements. Danish Minister Jacob Jensen noted NGTs "can help us do more with less" by enabling robust, resource-efficient crops.

The US regulatory picture became more complex in late 2024 when a federal court vacated the USDA SECURE Rule, reverting biotechnology crop review to pre-2020 procedures. Despite this uncertainty, gene-edited crops remain distinct from GMOs in US policy.

Globally, the momentum is positive. Japan treats gene-edited crops as non-GMO with a notification system. Argentina and Latin America have science-based frameworks treating non-transgenic edits as conventional breeding. The Philippines approved non-browning bananas as non-GMO in 2024. China issued its first plant gene editing safety certificates including for staple crops. And Brazil's December 2024 unified bioinputs law created the fastest approval pathway globally for biological products.

The regulatory tailwind compounds the technology tailwind—creating rare alignment between capability, economics, and policy.

We at Speciale Invest believe in supporting breakthrough technologies that have the potential to solve pressing global problems. As early-stage investors, we like to get our hands dirty early on and support founders in their zero-to-one journey with patient capital, business development opportunities, and hiring support. We enjoy and thrive on the risk that comes with backing deep-tech startups at the pre-product stage and help them through product-market fit, early customers, and scale-up.

To know more about Speciale's investments in disruptive technologies, please check our portfolio.